Timothy Kennedy, MD, MBA
Timothy Kennedy, MD, MBA, is a board-certified surgeon who specializes in the treatment of complex cancers in the liver, pancreas, bile duct, and upper gastrointestinal tract. Dr. Kennedy also serves as the system chief of surgical oncology at MedStar Health, John S. Dillon chair of surgical oncology at Georgetown University’s Department of Surgery, and surgeon in chief at Georgetown Lombardi Comprehensive Cancer Center.[1]
Education and Career
Dr. Kennedy attended Georgetown University for his undergraduate education, and after earning his Bachelor of Science in Biology, he remained at Georgetown University to attend its School of Medicine.
He completed an internship and General Surgery residency at Northwestern University in Evanston, Illinois, spending two years of his time there working in a basic science laboratory studying the development of pancreatic cancer.
He also attended Northwestern’s Kellogg School of Management, earning a Master’s in Business Administration with a focus on Healthcare Management and Strategy.[1]
Following his time at Northwestern, Dr. Kennedy completed a two-year surgical oncology fellowship at Memorial Sloan Kettering Cancer Center with a focus on gastric, pancreatic, and hepatobiliary malignancies. He pursued and completed a second fellowship there in advanced minimally invasive surgery, developing skills in advanced laparoscopic, endoscopic, and robotic techniques.
After completing his education, Dr. Kennedy spent six years as Assistant Professor of Surgery at Montefiore Medical Center/Albert Einstein College of Medicine in its section of upper gastrointestinal and pancreas surgery.
Dr. Kennedy is now a surgical oncologist with MedStar Health. He sees patients in the Washington D.C. area and is the surgeon in chief at the Georgetown Lombardi Comprehensive Cancer Center. He specializes in complex GI cancers, including peritoneal mesothelioma.
Dr. Kennedy’s skills include advanced laparoscopic and robotic techniques for GI cancers, as well as cytoreductive surgery and hyperthermic intraperitoneal (HIPEC) for the treatment of peritoneal surface malignancies and mesothelioma.[2]
Research
Dr. Kennedy has been actively involved in clinical trials throughout his career, including serving as principal investigator on a Phase II clinical trial utilizing CRS and HIPEC for patients with peritoneal surface malignancy from peritoneal mesothelioma, pseudomyxoma peritonei, appendiceal cancer, colon cancer, and gastric cancer.
His recent publications include the following articles on peritoneal mesothelioma:
Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study
Gazivoda, V. P., Kangas-Dick, A. W., Greenbaum, A. A., Roshal, J., Chen, C., Moore, D. F., Langan, R. C., Kennedy, T. J., Minerowicz, C. & Alexander, H. R., Sep 2022, In Journal of Surgical Research. 277, p. 131-137 7 p.
Treatment of Patients with Malignant Peritoneal Mesothelioma
Li, C. Y., Kennedy, T. & Alexander, H. R., Apr 1, 2022, In Journal of Clinical Medicine. 11, 7, 1891.
The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma.
Chicago Consensus Working Group, Jun 1, 2020, In: Cancer. 126, 11, p. 2547-2552 6 p.
